Notícias e Atividades da Mitsubishi Tanabe Pharma America
Presença
Mitsubishi Tanabe Pharma é uma empresa listada sob o símbolo 4508 (JP).
Mitsubishi Tanabe Pharma tem presença direta em 4 países.Mitsubishi Tanabe Pharma possui 3 subsidiárias incluindo Mitsubishi Tanabe Pharma America, Mitsubishi Tanabe Pharma Europe e NeuroDerm.
Fusão, aquisição e financiamento envolvendo Mitsubishi Tanabe Pharma.
Executivos
Veja o organograma con seus 18 executivos principais
Biografias mais buscadas da Mitsubishi Tanabe Pharma America
- Atsushi Fujimoto, President
- Gustavo Suarez, Vice President, Medical Affairs
- Andy Zylak, Country Manager, Canada
Criar um alerta
para seguir os movimentos de executivos da Mitsubishi Tanabe Pharma America.
Farmacêutica
Mitsubishi Tanabe Pharma possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).
Popular M&A news in Farmacêutica
- Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
- Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publicado em 12 de março de 2025).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America Announces Research Collaboration Between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to Advance Small Molecule Condensate Modulator for ALS - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America to Present New ALS Research at MNDA’s 35th International Symposium on ALS/MND - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America to Present Data on Investigational ND0612 at the 2024 Annual Meeting of the Parkinson Study Group - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA ORS® (edaravone) from a Phase 3b Efficacy and Safety Extension Study and a Clinical Analysis of Multiple Studies at NEALS 2024 - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America Unveils New ALS Research Findings at NEALS 2024 Annual Meeting - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2024 AANEM Annual Meeting - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America to Showcase New RADICAVA ORS® (edaravone) Real-World Data at 2024 Academy of Managed Care Pharmacy Nexus Meeting - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America to Discontinue Intravenous (IV) RADICAVA® (edaravone) - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America to Present RADICAVA ORS® (edaravone) Data at the 2024 National Association of Specialty Pharmacy Annual Meeting - Press Releases - Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America to Highlight Data on Investigational ND0612 at the 2024 International Congress of Parkinson’s Disease and Movement Disorders - Press Releases - Mitsubishi Tanabe Pharma America
- View more press releases Close
Redes sociais sobre Mitsubishi Tanabe Pharma America
- Mitsubishi Tanabe Pharma America na Wikipedia, Google News e Yahoo Finance
- Mitsubishi Tanabe Pharma America na LinkedIn, Twitter e YouTube
